ProQR Therapeutics (NASDAQ:PRQR) Receives $7.60 Average Price Target from Analysts

ProQR Therapeutics (NASDAQ:PRQR) has received an average rating of “Buy” from the five analysts that are presently covering the company, Marketbeat reports. Four equities research analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $7.60.

A number of analysts recently issued reports on PRQR shares. HC Wainwright reissued a “buy” rating and set a $10.00 target price on shares of ProQR Therapeutics in a research note on Thursday, December 12th. Raymond James raised ProQR Therapeutics from an “outperform” rating to a “strong-buy” rating and increased their target price for the stock from $6.00 to $14.00 in a research note on Tuesday, October 29th. JMP Securities reissued a “market outperform” rating and set a $8.00 target price on shares of ProQR Therapeutics in a research note on Thursday, December 12th. Chardan Capital reissued a “buy” rating and set a $4.00 target price on shares of ProQR Therapeutics in a research note on Thursday, December 12th. Finally, StockNews.com cut ProQR Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, November 28th.

ProQR Therapeutics Price Performance

Shares of NASDAQ:PRQR opened at $2.62 on Monday. The company has a market capitalization of $214.00 million, a price-to-earnings ratio of -8.19 and a beta of 0.30. The firm’s 50 day simple moving average is $3.29 and its 200 day simple moving average is $2.50. ProQR Therapeutics has a fifty-two week low of $1.61 and a fifty-two week high of $4.62.

Hedge Funds Weigh In On ProQR Therapeutics

Hedge funds have recently made changes to their positions in the business. BNP Paribas Financial Markets boosted its holdings in shares of ProQR Therapeutics by 14.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 58,801 shares of the biopharmaceutical company’s stock valued at $107,000 after buying an additional 7,300 shares during the last quarter. OneDigital Investment Advisors LLC boosted its holdings in shares of ProQR Therapeutics by 37.0% in the 3rd quarter. OneDigital Investment Advisors LLC now owns 57,550 shares of the biopharmaceutical company’s stock valued at $105,000 after buying an additional 15,550 shares during the last quarter. Finally, Privium Fund Management B.V. boosted its holdings in shares of ProQR Therapeutics by 0.9% in the 3rd quarter. Privium Fund Management B.V. now owns 5,632,388 shares of the biopharmaceutical company’s stock valued at $10,251,000 after buying an additional 51,663 shares during the last quarter. 32.65% of the stock is owned by institutional investors.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).